Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7% - Here's What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares were down 7% during mid-day trading on Monday . The stock traded as low as $18.34 and last traded at $18.58. Approximately 72,167 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 241,564 shares. The stock had previously closed at $19.99.

Analysts Set New Price Targets

DNTH has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating on the stock. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Stock Down 5.0 %

The company has a market cap of $517.86 million, a PE ratio of -6.45 and a beta of 1.62. The company has a 50-day moving average of $21.48 and a 200-day moving average of $23.92.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DNTH. R Squared Ltd bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter worth $33,000. KBC Group NV purchased a new position in Dianthus Therapeutics in the fourth quarter worth $35,000. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the 4th quarter valued at $59,000. Finally, AlphaQuest LLC increased its position in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after purchasing an additional 3,072 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.